Astrana Health to Present at J.P. Morgan 2026 Healthcare Conference, Showcasing AI-Driven Care Solutions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy ASTH?
Source: Newsfilter
- Leadership Participation: Astrana Health's leadership will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing their latest advancements in healthcare technology, which is expected to attract investor and industry attention.
- Technology-Driven Care: As a physician-centric company, Astrana Health supports over 20,000 providers and 1.6 million patients through its proprietary technology platform and aligned provider networks, driving the implementation of value-based care that enhances patient experiences and outcomes.
- Market Impact: Astrana Health's participation not only highlights its innovative capabilities in the healthcare sector but also has the potential to strengthen its position in a competitive market, attracting more partners and investments.
- Future Outlook: By showcasing its AI-driven care solutions at the conference, Astrana Health aims to further promote transformative changes in the healthcare system, leading to higher medical value and better patient outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASTH
Wall Street analysts forecast ASTH stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 20.910
Low
26.00
Averages
33.20
High
40.00
Current: 20.910
Low
26.00
Averages
33.20
High
40.00
About ASTH
Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Astrana Health Reports Record Financial Results for FY 2025
- Record Financial Performance: Astrana Health achieved a record revenue of $3.18 billion for FY 2025, representing a 56% increase from 2024, demonstrating the resilience of its risk-bearing, technology-driven healthcare model in a dynamic environment, further solidifying its market leadership.
- Significant Adjusted EBITDA Growth: The company reported an adjusted EBITDA of $205 million in 2025, up 20% year-over-year, reflecting that its efficient operational model and strong physician alignment have created measurable value for patients, enhancing accessibility and quality of care.
- Expanded Stock Repurchase Program: The Board of Directors increased the maximum amount for the stock repurchase program from $50 million to $100 million, which is expected to be executed through various methods, aiming to enhance shareholder value and reflect confidence in the company's stock.
- Optimistic 2026 Growth Guidance: Astrana anticipates approximately 24% revenue growth and 29% adjusted EBITDA growth for 2026, indicating that the integration of Prospect Health is ahead of schedule and will continue to drive sustainable growth moving forward.
See More
Astrana Health Q4 Earnings Exceed Expectations
- Strong Earnings Report: Astrana Health reported a Q4 Non-GAAP EPS of $0.54, beating expectations by $0.21, which highlights the company's significant profitability improvement and boosts market confidence in its future growth.
- Revenue Growth: The company achieved Q4 revenue of $950.5 million, a 42.9% year-over-year increase, surpassing market expectations by $20.04 million, indicating strong competitive positioning and robust customer demand.
- Care Partners Performance: The Care Partners segment generated revenue of $892.5 million, up 38% from $647.7 million last year, reflecting the company's successful expansion in value-based care and effective strategic execution.
- Future Guidance: Astrana provided a positive outlook for 2026, projecting total revenue between $900 million and $1 billion and Adjusted EBITDA between $60 million and $70 million, demonstrating the company's optimistic view of future market conditions.
See More
Analysis of Potential and Risks in Small-Cap Stocks
- Shoe Carnival Risk Assessment: Shoe Carnival (SCVL) has a market cap of $566.1 million, with weak same-store sales trends over the past two years indicating limited expansion opportunities in core markets, and its revenue base of $1.14 billion has not achieved the economies of scale enjoyed by larger competitors, leading to declining earnings per share and reduced profitability.
- Ocular Therapeutix Challenges: Ocular Therapeutix (OCUL) boasts a market cap of $2.09 billion, but has faced a 5.7% annual sales decline over the last two years, with its adjusted operating margin decreasing by 340.5 percentage points over five years, highlighting significant market demand issues and increased capital intensity.
- Astrana Health Growth Potential: Astrana Health (ASTH), with a market cap of $1.05 billion, has demonstrated impressive annual revenue growth of 47.7% over the past two years, indicating a significant increase in market share, and its revenue outlook for the next 12 months remains outstanding, suggesting successful participation in value-based payment models.
- Investment Recommendations: While the small-cap market is filled with potential, the risks associated with companies like Shoe Carnival and Ocular Therapeutix urge investors to be cautious, whereas Astrana Health may represent a compelling investment opportunity, reflecting market preferences for high-growth firms.
See More
Surge in Options Trading Volume for Okta and Astrana Health
- Okta Options Volume: Okta Inc experienced options trading volume of 28,412 contracts, equivalent to approximately 2.8 million shares, representing 101.8% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Put Option Activity: Within Okta, the $50 strike put option expiring on September 18, 2026, saw 12,002 contracts traded today, representing about 1.2 million underlying shares, suggesting heightened investor expectations for a potential price decline.
- Astrana Options Trading: Astrana Health Inc recorded options trading volume of 5,439 contracts, approximately 543,900 shares, which is about 89.7% of its average daily trading volume over the past month, reflecting growing market interest in the company.
- High Call Option Activity: For Astrana, the $25 strike call option expiring on March 20, 2026, saw 5,397 contracts traded today, representing around 539,700 shares, indicating optimistic investor sentiment regarding its future performance.
See More
Astrana Health Stock Plummets 22% Amid Medicare Payment Concerns
- Significant Stock Drop: Astrana Health Inc. shares fell approximately 22% to close at $21.48 on Tuesday, primarily due to CMS's proposed 0.09% payment growth for Medicare Advantage in 2027, indicating weak payment growth that could impact future revenues.
- High Revenue Dependency: Analysts noted that Medicare accounts for about 61% of Astrana Health's revenue, and despite the sharp decline, the stock's drop was more severe than peers like Agilon Health and Alignment Healthcare, which fell around 10% and 12%, respectively, reflecting greater market concerns about Astrana.
- Differentiated Risk Adjustment Practices: Analyst William Blair highlighted that Astrana Health's risk adjustment practices differ from larger payers, relying on direct patient care rather than audio-only visits or standalone chart reviews, resulting in lower exposure to the risk score impacts proposed by CMS.
- Long-Term Value Potential: Despite short-term pressures, analysts believe that CMS's proposals could enhance the company's long-term value, as payers will need to rely on fully delegated care delivery partners to manage patients and costs, potentially leading to more delegated contract agreements in 2027 and beyond.
See More
Astrana Health to Present at 2026 JP Morgan Healthcare Conference, Showcasing AI Innovations
- Conference Participation: Astrana Health will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing its latest advancements in healthcare technology, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the healthcare sector.
- Technology-Driven: As a physician-centric, AI-powered healthcare company, Astrana Health supports over 20,000 providers and 1.6 million patients through its proprietary technology platform and aligned provider networks, driving the implementation of value-based care that enhances patient experiences and outcomes.
- Market Positioning: Astrana Health's business model integrates scalable care delivery infrastructure with proactive preventive care capabilities, aiming to improve the overall value of the healthcare system and strengthen the company's strategic position in a competitive healthcare market.
- Future Outlook: By participating in key industry conferences, Astrana Health not only showcases its technological innovations but also paves the way for future investment opportunities, further solidifying its leadership position in the healthcare sector.
See More
Astrana Health Reports Record Financial Results for FY 2025
- Record Financial Performance: Astrana Health achieved a record revenue of $3.18 billion for FY 2025, representing a 56% increase from 2024, demonstrating the resilience of its risk-bearing, technology-driven healthcare model in a dynamic environment, further solidifying its market leadership.
- Significant Adjusted EBITDA Growth: The company reported an adjusted EBITDA of $205 million in 2025, up 20% year-over-year, reflecting that its efficient operational model and strong physician alignment have created measurable value for patients, enhancing accessibility and quality of care.
- Expanded Stock Repurchase Program: The Board of Directors increased the maximum amount for the stock repurchase program from $50 million to $100 million, which is expected to be executed through various methods, aiming to enhance shareholder value and reflect confidence in the company's stock.
- Optimistic 2026 Growth Guidance: Astrana anticipates approximately 24% revenue growth and 29% adjusted EBITDA growth for 2026, indicating that the integration of Prospect Health is ahead of schedule and will continue to drive sustainable growth moving forward.
See More
Astrana Health Q4 Earnings Exceed Expectations
- Strong Earnings Report: Astrana Health reported a Q4 Non-GAAP EPS of $0.54, beating expectations by $0.21, which highlights the company's significant profitability improvement and boosts market confidence in its future growth.
- Revenue Growth: The company achieved Q4 revenue of $950.5 million, a 42.9% year-over-year increase, surpassing market expectations by $20.04 million, indicating strong competitive positioning and robust customer demand.
- Care Partners Performance: The Care Partners segment generated revenue of $892.5 million, up 38% from $647.7 million last year, reflecting the company's successful expansion in value-based care and effective strategic execution.
- Future Guidance: Astrana provided a positive outlook for 2026, projecting total revenue between $900 million and $1 billion and Adjusted EBITDA between $60 million and $70 million, demonstrating the company's optimistic view of future market conditions.
See More
Analysis of Potential and Risks in Small-Cap Stocks
- Shoe Carnival Risk Assessment: Shoe Carnival (SCVL) has a market cap of $566.1 million, with weak same-store sales trends over the past two years indicating limited expansion opportunities in core markets, and its revenue base of $1.14 billion has not achieved the economies of scale enjoyed by larger competitors, leading to declining earnings per share and reduced profitability.
- Ocular Therapeutix Challenges: Ocular Therapeutix (OCUL) boasts a market cap of $2.09 billion, but has faced a 5.7% annual sales decline over the last two years, with its adjusted operating margin decreasing by 340.5 percentage points over five years, highlighting significant market demand issues and increased capital intensity.
- Astrana Health Growth Potential: Astrana Health (ASTH), with a market cap of $1.05 billion, has demonstrated impressive annual revenue growth of 47.7% over the past two years, indicating a significant increase in market share, and its revenue outlook for the next 12 months remains outstanding, suggesting successful participation in value-based payment models.
- Investment Recommendations: While the small-cap market is filled with potential, the risks associated with companies like Shoe Carnival and Ocular Therapeutix urge investors to be cautious, whereas Astrana Health may represent a compelling investment opportunity, reflecting market preferences for high-growth firms.
See More
Surge in Options Trading Volume for Okta and Astrana Health
- Okta Options Volume: Okta Inc experienced options trading volume of 28,412 contracts, equivalent to approximately 2.8 million shares, representing 101.8% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Put Option Activity: Within Okta, the $50 strike put option expiring on September 18, 2026, saw 12,002 contracts traded today, representing about 1.2 million underlying shares, suggesting heightened investor expectations for a potential price decline.
- Astrana Options Trading: Astrana Health Inc recorded options trading volume of 5,439 contracts, approximately 543,900 shares, which is about 89.7% of its average daily trading volume over the past month, reflecting growing market interest in the company.
- High Call Option Activity: For Astrana, the $25 strike call option expiring on March 20, 2026, saw 5,397 contracts traded today, representing around 539,700 shares, indicating optimistic investor sentiment regarding its future performance.
See More
Astrana Health Stock Plummets 22% Amid Medicare Payment Concerns
- Significant Stock Drop: Astrana Health Inc. shares fell approximately 22% to close at $21.48 on Tuesday, primarily due to CMS's proposed 0.09% payment growth for Medicare Advantage in 2027, indicating weak payment growth that could impact future revenues.
- High Revenue Dependency: Analysts noted that Medicare accounts for about 61% of Astrana Health's revenue, and despite the sharp decline, the stock's drop was more severe than peers like Agilon Health and Alignment Healthcare, which fell around 10% and 12%, respectively, reflecting greater market concerns about Astrana.
- Differentiated Risk Adjustment Practices: Analyst William Blair highlighted that Astrana Health's risk adjustment practices differ from larger payers, relying on direct patient care rather than audio-only visits or standalone chart reviews, resulting in lower exposure to the risk score impacts proposed by CMS.
- Long-Term Value Potential: Despite short-term pressures, analysts believe that CMS's proposals could enhance the company's long-term value, as payers will need to rely on fully delegated care delivery partners to manage patients and costs, potentially leading to more delegated contract agreements in 2027 and beyond.
See More
Astrana Health to Present at 2026 JP Morgan Healthcare Conference, Showcasing AI Innovations
- Conference Participation: Astrana Health will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco, showcasing its latest advancements in healthcare technology, which is expected to attract investor and industry attention, thereby enhancing the company's visibility in the healthcare sector.
- Technology-Driven: As a physician-centric, AI-powered healthcare company, Astrana Health supports over 20,000 providers and 1.6 million patients through its proprietary technology platform and aligned provider networks, driving the implementation of value-based care that enhances patient experiences and outcomes.
- Market Positioning: Astrana Health's business model integrates scalable care delivery infrastructure with proactive preventive care capabilities, aiming to improve the overall value of the healthcare system and strengthen the company's strategic position in a competitive healthcare market.
- Future Outlook: By participating in key industry conferences, Astrana Health not only showcases its technological innovations but also paves the way for future investment opportunities, further solidifying its leadership position in the healthcare sector.
See More
